Compare Icl Group Ltd (ICL) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Tenet Healthcare Corporation — how do they compare? Icl Group Ltd trades at $5.26 (market cap $6.65B), while Tenet Healthcare Corporation trades at $197 (market cap $16.74B). The key difference: Tenet Healthcare Corporation is far larger — about 2.5× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.77% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| ICL | THC | |
|---|---|---|
Market Cap | $6.65B | $16.74B |
Sector | Basic Materials | Health |
52-Week High | $7.03 | $244.80 |
52-Week Low | $4.80 | $148.38 |
Enterprise Value | $9.22B | $26.99B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.00, down 0.99% over 24 hours, with a bearish technical signal. The company reported Q1 2026 earnings of $0.11 per share, beating estimates, and recently completed an $800 million senior notes offering. Revenue for 2025 was $7.15 billion with a net income margin of 3.15%, while valuation ratios show a P/E of 24.05 and P/S of 0.88. Analyst consensus is entirely hold-rated, reflecting cautious sentiment amid mixed financial trends.
The outlook for ICL is neutral with modest growth potential, supported by operational improvements and raised 2026 EBITDA guidance. Key risks include elevated raw material costs, foreign exchange headwinds, and competitive pressures in the specialty minerals sector. Investors should weigh stable cash flows against margin compression and debt levels from recent financing activities.
Tenet Healthcare (THC) trades at $194.38, down 0.27% on the day, with a neutral technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $4.82 exceeding expectations of $4.17. Valuation metrics appear attractive with a P/E of 10.14 and P/S of 0.79, while profitability remains robust with 82.47% gross margins and 37.87% ROE. Recent news highlights the company's expanding outpatient footprint through USPI as a key growth driver.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $235.88 price target representing 21% upside potential. The company's solid earnings momentum and defensive healthcare positioning during market volatility provide stability. Key risks include execution challenges in outpatient expansion and potential regulatory headwinds affecting hospital operations. Cash flow trends show improvement with projected net cash flow narrowing from -$136M in 2025 to -$32M in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
